Peptides News and Research

RSS

Positive results from Aeterna Zentaris' AEZS-108 Phase 2 study in ovarian cancer patients

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with platinum-resistant and taxane-pretreated ovarian cancer.

2 Nov 2009

Amylin and Takeda to develop and commercialize pharmaceutical products for obesity

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.

2 Nov 2009

NCI awards $4.8M for project to measure all the proteins in the human body

An expert in cancer proteomics at Fred Hutchinson Cancer Research Center has received $4.8 million in federal stimulus funding from the National Cancer Institute to co-lead a pilot study to assess the feasibility and scalability of a project that aims to measure all of the proteins in the human body.

31 Oct 2009

Studies demonstrate that investigational cancer vaccines show encouraging immune response rates

Results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in advanced melanoma, prostate cancer and other solid malignancies, setting the stage for phase 2 studies.

30 Oct 2009

Roche discloses the results of first Phase III clinical study using Taspoglutide

Ipsen (Paris:IPN), an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed the results of a first phase III clinical study using Taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen’s Research.

29 Oct 2009

Helix BioMedix' SmartPeptides technology products demonstrate improvement in skin texture

Helix BioMedix, Inc., a developer of bioactive peptides, today announced the completion of a series of three clinical studies investigating the safety and efficacy of a serum, eye cream and moisturizer, each containing the Company’s SmartPeptides™ technology, including the newly developed Heptapeptide-7. These studies demonstrate improvement in skin texture and appearance as well as the decrease in fine lines and wrinkles with Striking™ Skin Care formulations.

28 Oct 2009

NCI funds pilot study to measure human proteins

28 Oct 2009

URI scientists discover a new and effective approach for treating cancerous tumor

Two University of Rhode Island associate professors, biophysicists Yana Reshetnyak and Oleg Andreev, have discovered a technology that can detect cancerous tumors and deliver treatment to them without the harming the healthy cells surrounding them, thereby significantly reducing side effects.

27 Oct 2009

Quark Pharmaceuticals receives a Japanese patent for its hypoxia regulated genes

Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced issuance of Japanese Patent Number: 4354633, titled, "Hypoxia regulated genes," on August 7, 2009.

27 Oct 2009

Overview of Compugen’s DAC Blockers Platform presented at Fifth Peptide Engineering Meeting

Speaking today in Barcelona at the Fifth Peptide Engineering Meeting, Compugen Ltd. project manager Dr. Yossef Kliger provided an overview of Compugen’s DAC Blockers Platform and reviewed disease model data for selected product candidates.

26 Oct 2009

Comparison study between pre and postoperative BNP measurements for predicting negative outcomes after CABG surgery

Results from a clinical study presented at the 2009 American Society of Anesthesiologists (ASA) Meeting suggest that elevated preoperative levels of the B-type natriuretic peptide (BNP) biomarker may predict hospital length of stay and mortality after primary coronary artery bypass graft surgery better than measurements of elevated postoperative BNP levels.

26 Oct 2009

Eurogentec to acquire Anaspec, a private proteomics company in California

Eurogentec S.A. (“Eurogentec”) announces today a final agreement for the acquisition of AnaSpec, Inc. (“AnaSpec” or the “Company”), a privately-held proteomics company based in Fremont, California.

24 Oct 2009

TransMolecular announces final results from its Phase 2 clinical study of 131I-TM601

TransMolecular, Inc., a developer of innovative oncology drugs through targeted delivery technologies, today announced final results from its Phase 2 clinical study comparing the toxicity and overall survival of three versus six intracavitary injections of its anti-cancer compound 131I-TM601 in the treatment of recurrent malignant glioma.

24 Oct 2009

Medtronic announces ONSET trial results of sensor-enhanced CSII in children

Medtronic, Inc. today announced study results from an oral presentation at the International Diabetes Federation’s World Diabetes Congress held in Montreal, Canada. This scientific convention highlights the latest developments in clinical research aimed at improving diabetes management and outcomes.

23 Oct 2009

Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab

Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.

22 Oct 2009

Controlled formation of patchy particles may serve as drug-delivery vehicles to combat disease

Physicists, chemists and engineers at the University of Pennsylvania have demonstrated a novel method for the controlled formation of patchy particles, using charged, self-assembling molecules that may one day serve as drug-delivery vehicles to combat disease and perhaps be used in small batteries that store and release charge.

21 Oct 2009

Oncolytics Biotech invests in BCBC; purchases convertible shares in exchange for common shares

Oncolytics Biotech Inc. ("Oncolytics") announced today that it has made an investment in British Canadian Biosciences Corp. (BCBC), a privately held biotechnology company specializing in the development of peptides for the treatment of a variety of conditions, including cancer.

21 Oct 2009

Research shows exon-skipping drug may prove effective for treating Duchenne muscular dystrophy

An exon skipping PPMO has demonstrated dramatic effects in the prevention and treatment of severely affected, dystrophin and utrophin-deficient mice, preventing severe deterioration of the treated animals and extending their lifespan.

21 Oct 2009

Positive results from KAI Pharmaceuticals' pain therapeutic program

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, announced positive preclinical results from its program targeting the gamma protein kinase C (PKC) pathway for the development of novel therapies for pain.

20 Oct 2009

Researchers use biotechnological tools to find a cure for Alzheimer's disease

No one has yet found a cure or a way to prevent people from developing Alzheimer's disease. Researchers from the Swedish University of Agricultural Sciences, among others, are breaking new ground in biotechnology to find new tools that can help provide new solutions.

20 Oct 2009

Peptides News and Research

Positive results from Aeterna Zentaris' AEZS-108 Phase 2 study in ovarian cancer patients

Amylin and Takeda to develop and commercialize pharmaceutical products for obesity

NCI awards $4.8M for project to measure all the proteins in the human body

Studies demonstrate that investigational cancer vaccines show encouraging immune response rates

Roche discloses the results of first Phase III clinical study using Taspoglutide

Helix BioMedix' SmartPeptides technology products demonstrate improvement in skin texture

NCI funds pilot study to measure human proteins

URI scientists discover a new and effective approach for treating cancerous tumor

Quark Pharmaceuticals receives a Japanese patent for its hypoxia regulated genes

Overview of Compugen’s DAC Blockers Platform presented at Fifth Peptide Engineering Meeting

Comparison study between pre and postoperative BNP measurements for predicting negative outcomes after CABG surgery

Eurogentec to acquire Anaspec, a private proteomics company in California

TransMolecular announces final results from its Phase 2 clinical study of 131I-TM601

Medtronic announces ONSET trial results of sensor-enhanced CSII in children

Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab

Controlled formation of patchy particles may serve as drug-delivery vehicles to combat disease

Oncolytics Biotech invests in BCBC; purchases convertible shares in exchange for common shares

Research shows exon-skipping drug may prove effective for treating Duchenne muscular dystrophy

Positive results from KAI Pharmaceuticals' pain therapeutic program

Researchers use biotechnological tools to find a cure for Alzheimer's disease

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News